COG 1410
Alternative Names: COG-1410Latest Information Update: 28 Jan 2022
At a glance
- Originator Duke University
- Developer Cognosci
- Class Anti-inflammatories; Antidementias; Antihaemorrhagics; Neuropeptides; Neuroprotectants; Small molecules
- Mechanism of Action Apolipoprotein E agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alzheimer's disease; Traumatic brain injuries
- Discontinued Subarachnoid haemorrhage
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 28 Jan 2022 No recent reports of development identified for preclinical development in Traumatic-brain-injuries in USA
- 03 Jan 2020 COG 1410 is available for licensing as of 03 Jan 2020. http://www.cognosci.com/partnering.html (Cognosci Pipeline, January 2020)